Get The Alerts + Report

Bicara Therapeutics Inc. [BCAX]

Reporting date: 10/09/2025

⚠️ Neutral Insider Mix Detected

📝 What Happened

  • Insider: Raben David; Hyep Ivan
  • Role: Chief Medical Officer; Chief Financial Officer
  • Company: Bicara Therapeutics Inc. (BCAX)
  • Transaction Date(s): 2025-10-09
  • Table I (Non-Derivative Securities)
    • Sale : 28,415
    • Average Sale Price: $18.40
    • Total Value: $522,831.34
    • Post-Transaction Direct Holdings: 180,852
    • Indirect Holdings: None reported
    • 10b5-1 Plan Used? Yes

    📄 Summary

    Raben David and Hyep Ivan, Chief Medical Officer and Chief Financial Officer at Bicara Therapeutics Inc. (BCAX), executed mixed transactions (option exercises followed by sales), selling a total of 28,415 shares on October 9, 2025, at an average price of $18.40, realizing proceeds of about ~$522,831. After the transactions, they now hold a combined direct position of 180,852 common shares and report no indirect holdings. For retail traders, this is a neutral-to-slightly-bearish event: routine 10b5-1-driven sales after low-cost option exercises, likely profit-taking.

    🔑 Interpretation

    The transactions appear largely execution of compensation-related option exercises followed by systematic sales under Rule 10b5-1 plans, capturing the spread between the exercise price (~$3.79) and market sale prices (~$18.2–$18.45). These are plan-driven and look like planned liquidity events rather than opportunistic ad-hoc insider dumping.

    🔑 Interpretation

    • Type: Comp-related (10b5-1 plan driven) rather than purely discretionary
    • Disposition: Shares were sold as reported (sales executed), likely immediately following exercise under the plan
    • Size Context: Combined sale of 28,415 shares is meaningful relative to the exercised amounts (they exercised and sold the newly acquired shares); for the CFO the sale was a small percentage of total holdings, for the CMO it represented sale of the exercised tranche — overall looks like routine profit-taking
    • ATH Metric: The sales at ~$18.2–$18.45 are well above the exercise/conversion price (~$3.79), indicating capture of gains. Based on recent trading in the high-teens (using the sale prices as proximate recent levels), these trades do not appear to be occurring at an obvious all-time high or all-time low for the stock and look opportunistic relative to the low exercise price rather than timed to market extremes.
    • Outlier Check: Not unusually large given the simultaneous exercises and subsequent sales under 10b5-1 plans; sizes align with option vesting/exercise tranches and are not extreme outliers versus the officers' post-transaction holdings.

    📊 Bullish or Bearish?

    Decide: Neutral

    Neutral. The filings show option exercises (code M) immediately followed by sales (code S) executed under Rule 10b5-1 plans, indicating planned liquidity and profit-taking rather than a discretionary signal of negative company prospects; sales are meaningful but tied to compensation mechanics and the dataset is limited to these filings. Cluster activity cannot be determined from this filing alone.

    ✅ Bottom Line (Retail Takeaway)

    This transaction looks like routine profit-taking tied to option exercises and 10b5-1 plans rather than a definitive bearish signal. For retail traders, it’s likely noise — not a standalone trade trigger unless multiple unrelated insiders begin large, discretionary sales.